Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27012450 | 1.00 | TLR9 (0.34) | TLR9TLR8TLR7HRH3CCR2 | |
| SCHEMBL22520631 | 0.92 | HRH3 (0.35) | TLR9TLR8TLR7HRH3KCNH2 | |
| SCHEMBL27013290 | 0.89 | HRH3 (0.33) | HRH3CYP2D6 | |
| SCHEMBL27012443 | 0.89 | HRH3 (0.33) | HRH3CYP2D6 | |
| SCHEMBL27012454 | 0.88 | TLR9 (0.36) | TLR9TLR8TLR7HRH3CCR2 | |
| SCHEMBL27027629 | 0.88 | TLR9 (0.36) | TLR9TLR8TLR7HRH3CCR2 | |
| SCHEMBL27012455 | 0.87 | TLR9 (0.35) | TLR9TLR8TLR7HRH3CCR2 | |
| SCHEMBL24233104 | 0.87 | TSHR (0.35) | TLR9TLR8TLR7HRH3CCR2 | |
| SCHEMBL24475321 | 0.85 | HRH3 (0.32) | HRH3 | |
| SCHEMBL27016087 | 0.85 | HRH3 (0.32) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018123-A1 | COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20240018123-A1 | COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018123-A1 | COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF | AR, NR5A1, SHBG | TLR9 1017/4885TLR8 1370/4885TLR7 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.